Sarcouncil Journal of Internal Medicine and Public Health

Abstract: We read with interest the article by Kang, et al. on a retrospective, national, multicenter study on the adverse events (AED) of remdesivir in 2416 patients with SARS-CoV-2 infection (SC2I), collected during an observational period of one year (January to December 2021) [Kang, H. et al., 2023]. It was found that 66.2% of patients experienced at least one AED and 13.8% experienced at least one severe AED [Kang, H. et al., 2023]. The incidence of AEDs was not increased in patients with SC2I receiving remdesivir compared to controls, but the AED incidence was increased in patients with renal insufficiency [Kang, H. et al., 2023]. The most common severe AEDs in this group were anaemia, hypokalemia, and thrombocytopenia [Kang, H. et al., 2023]. It was concluded that remdesivir should be administered with caution in patients with renal insufficiency [Kang, H. et al., 2023]. The study is impressive, but some points require discussion.